Home » Business News » 2011 » June » June 9, 2011

Consumer Focus on Well-Being Provides Strength in Sector - Insight on Lifevantage Corporation and Radient Pharmaceuticals Corporation

June 9, 2011 - Beijing

Today, announced its research report highlighting Lifevantage Corporation (OTCBB: LFVN) and Radient Pharmaceuticals Corporation (NYSE Amex: RPC). Full report download is available at

This sector displays renewed investor interest as new and lucrative therapies are coming to market. The FDA approved the first new drug in 50 years to treat auto-immune disorder lupus in March 2011, and we expect approval of new treatments for Hepatitis C virus around mid-year.

Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help shorten the development timeline and limit expense and drug price growth. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas.
Global Equity is reporting on Lifevantage Corporation as a dietary supplement company, which focuses on improving life through anti-aging and wellness products, while creating business opportunities. LFVN the maker of Protandim®, a clinically demonstrated, science-based therapy for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that a new peer-reviewed review article involving Protandim® was published in the scientific journal Enzyme Research. The full report and profile on Lifevantage Corporation (OTCBB: LFVN) is available here:

Global Equity Reporter brings Radient Pharmaceuticals Corporation as it focuses on discovery, development and commercialization of diagnostic tests that help physicians answer clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. In December 2010, the Company in partnership with Jaiva Technologies, announced the formation of NuVax Therapeutics, Inc. The full report and profile on Radient Pharmaceuticals Corporation (NYSE Amex: RPC) is available here:

About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research - providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers. We report potential market opportunity to our members before the same situation grows to become strong market momentum, enabling our members to see strong market growth by delivering information before the crowd.


Alexander Griffin
Email Contact


Comment on this story